Matthew Johnson, PhD

Dr. Johnson is an experimental psychologist conducting human research on psychedelics and behavior change. From 2004 to 2024 he conducted seminal psychedelic research at Johns Hopkins, playing a role in the revival of psychedelic research. In 2024 he joined Sheppard Pratt to expand his psychedelic research. He has published research on psychedelics in relation to mystical experience, personality change, tobacco addiction, cancer distress, depression, and risks/safety guidelines. In 2021 he received the first grant in 50 years from the US government to administer a classic psychedelic as a treatment. He is also known for his expertise in behavioral economics, addiction, sexual risk behavior, and research across drug classes.